Table 3.
Summary of findings with potential to indicate mechanisms underlying clinical efficacy in alemtuzumab-treated patients
| Measure | Change relative to M0 |
|---|---|
| % regulatory T cells (Treg: CD4+CD25hiCD127lo/neg foxP3+) | Sustained increase from M5 through M23 (Fig. 1) |
| % effector T cells (Teff: CD4+CD25+CD127+foxP3-) | No change from M0 (Fig. 1) |
| Ratio of Teff:Treg in PBMC | Sustained reduction from M0 through M23 (Fig. 1) |
| Regulatory T cell function | Increased at M5 and M17 (Fig. 1) |
| % memory B cells (CD19+CD27+) | Sustained reduction from M5 through M36 (Fig. 3) |
| % naïve “regulatory” B cells (CD19+CD20+CD27-CD24hiCD38hi) | Sustained increase from M5 through M23 (Fig. 3) |
| Ratio of memory B cells:naïve “regulatory” B cells | Sustained reduction from M5 through M23 (Fig. 3) |
| % NK cells (CD3-CD56+) | Sustained increase from M5 through M23 (Fig. 4) |
| % "regulatory" NK cells (CD3-CD56bright) | Sustained increase from M5 through M36 (Fig. 4) |
| Ratio of NKT cells:CD3-CD56bright | Sustained reduction from M5 through M36 (Fig. 4) |
| IL-2 (pg/mL) | Sustained reduction from M5 through M23 (Fig. S4) |
| IFN-γ (pg/mL) | Sustained reduction from M5 through M23 (Fig. S4) |
| IL-17A (pg/mL) | Sustained reduction at M5, M11 and M23 (Fig. S4) |
| IL-10 (pg/mL) | No change from M0 (Fig. S4) |